Aspira Women's Health Inc. (AWH): Price and Financial Metrics
AWH Price/Volume Stats
| Current price | $3.39 | 52-week high | $6.75 |
| Prev. close | $3.50 | 52-week low | $2.31 |
| Day low | $3.39 | Volume | 7,800 |
| Day high | $3.52 | Avg. volume | 30,878 |
| 50-day MA | $3.70 | Dividend yield | N/A |
| 200-day MA | $4.00 | Market Cap | 41.85M |
AWH Stock Price Chart Interactive Chart >
Aspira Women's Health Inc. (AWH) Company Bio
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
Latest AWH News From Around the Web
Below are the latest news stories about ASPIRA WOMEN'S HEALTH INC that investors may wish to consider to help them evaluate AWH as an investment opportunity.
Aspira Women’s Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it will host a virtual R&D day featuring experts who will present the exciting progress of the company’s product pipeline on January 4, 2024 at 11:00 AM ET. To register, click here. Upcoming R&D Day: Aspira R&D Day: Updates on the Development of |
Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024Aspira management will be available for meetings in San Francisco (January 8-10, 2024) AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will be available for partnering and institutional one-on-one meetings in San Francisco, during JP Morgan’s Healthcare Conference Week 2024. Nicole |
New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10:30 PM PTNew to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10;30 PM PT Episode 537: 1). Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) 2). Aspira Women's Health (NASDAQ: AWH) ($AWH) 3). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 4).The Business of Blockchain, 5).Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.newtothestreet.com/ NEW YORK, Dec. 08, 202 |
New to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PTNew to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PT Episode 536: 1). - Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) 2). Aspira Women's Health (NASDAQ: AWH) ($AWH) 3). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 4). The Business of Blockchain 5).Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.ne |
Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for EndometriosisData supports EndoCheck™ to be the first blood test for the identification of localized endometriosis, including endometrioma Platform migration to begin on the Company’s EndoMDx™ test for broader endometriosis indications AUSTIN, Texas, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has completed the de |
AWH Price Returns
| 1-mo | -4.78% |
| 3-mo | -20.98% |
| 6-mo | -26.30% |
| 1-year | -35.43% |
| 3-year | -96.26% |
| 5-year | -83.01% |
| YTD | -16.91% |
| 2023 | -18.22% |
| 2022 | -81.21% |
| 2021 | -73.62% |
| 2020 | 728.40% |
| 2019 | 170.00% |
Loading social stream, please wait...